广济药业：第三季度净亏损2178.36万元

Core Viewpoint - Guangji Pharmaceutical reported a decline in revenue and a net loss for the third quarter of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 145 million yuan in the third quarter of 2025, representing a year-on-year decrease of 12.57% [1] - The net profit attributable to shareholders was a loss of 21.7836 million yuan [1] - The basic earnings per share were reported at -0.0628 yuan [1]